# SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma

Source: https://onco.cc/key-papers/paper-spearhead-1-lancet-2024/  
OnCo record `paper-spearhead-1-lancet-2024` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

T cells taken from patients and engineered to recognise the MAGE-A4 protein shrank tumours in about four in ten patients with advanced synovial sarcoma, leading to the first approval of a TCR T-cell therapy for any solid cancer.

## Summary

Single-arm phase 2 trial of 52 patients (44 with synovial sarcoma, 8 with myxoid/round cell liposarcoma) who were HLA-A*02 positive with MAGE-A4-expressing tumours, previously treated with anthracycline or ifosfamide, treated with a single infusion of afamitresgene autoleucel (afami-cel), autologous T cells expressing an affinity-enhanced MAGE-A4-specific T-cell receptor, after lymphodepleting chemotherapy. Primary endpoint was objective response rate.

The response rate was 37% overall and 39% in synovial sarcoma, with a median duration of response of about 12 months. Cytokine release syndrome occurred in about 70% but was mostly low grade. It led to FDA accelerated approval in 2024 (Tecelra), the first TCR-T and the first engineered cell therapy approved for a solid tumour.

## Fields

- Kind: Key paper
- Last checked: 2026-09-08
- Journal: The Lancet
- Year: 2024
- DOI: 10.1016/S0140-6736(24)00319-2
- Authors: D'Angelo SP, Araujo DM, Abdul Razak AR, et al.
- Findings: Objective response 37% overall (19 of 52); 39% in synovial sarcoma and 25% in myxoid/round cell liposarcoma.; Median duration of response about 12 months; median PFS about 3.8 months and median OS about 15 months in a heavily pretreated population.; Cytokine release syndrome in about 70% of patients, grade 3 in around 2%; cytopenias were common after lymphodepletion.; Eligibility required both HLA-A*02 genotype and MAGE-A4 expression, satisfied by roughly a third of screened synovial sarcoma patients.; Manufacturing success was high but the process took several weeks per patient.
- What it means: Patients with advanced synovial sarcoma, a rare cancer of young adults with few effective drugs, now have an approved cell therapy that produces responses lasting about a year in a substantial minority, if their tissue type and tumour antigen match. It proves that engineered T cells can work against a solid tumour when a good target is present, which had been elusive. It is not a cure for most, requires specialised centres, and only a minority of patients are eligible.
- Caveats: Single-arm trial with a response-rate endpoint; no randomised comparison and OS benefit is unproven.; Restricted to HLA-A*02-positive patients, which excludes many people of non-European ancestry.; Responses are usually not durable beyond a year; mechanisms of relapse (antigen loss, T-cell exhaustion) are being studied.; Very high cost and complex logistics for a rare indication.

## Sources

- PubMed search: SPEARHEAD-1 afamitresgene autoleucel Lancet: https://pubmed.ncbi.nlm.nih.gov/?term=SPEARHEAD-1+afamitresgene+autoleucel+synovial+sarcoma+Lancet
- ClinicalTrials.gov NCT04044768: https://clinicaltrials.gov/study/NCT04044768
- PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=SPEARHEAD-1%20afamitresgene%20autoleucel%20synovial%20sarcoma%20D'Angelo%20Lancet%202024

## Connected records

- key papers: [C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed](https://onco.cc/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/)
- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Synovial sarcoma](https://onco.cc/cancers/synovial-sarcoma/)
- technologies: [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [MAGE-A4](https://onco.cc/targets/mage-a4/)
- drugs: [Afamitresgene autoleucel](https://onco.cc/drugs/afamitresgene-autoleucel/), [Letetresgene autoleucel](https://onco.cc/drugs/letetresgene-autoleucel/)
- companies: [Adaptimmune](https://onco.cc/companies/adaptimmune/)
- terms: [Accelerated approval](https://onco.cc/terms/accelerated-approval/), [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [Objective response rate (ORR)](https://onco.cc/terms/orr/)
- people: [Jean-Yves Blay](https://onco.cc/people/jean-yves-blay/), [Sandra P. D'Angelo](https://onco.cc/people/sandra-dangelo/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- journals: [The Lancet](https://onco.cc/journals/lancet/)
- ideas: [Extending sarcoma TCR-T beyond HLA-A*02](https://onco.cc/ideas/idea-tcr-t-beyond-hla-a2/)

---
JSON: https://onco.cc/api/v1/entities/paper-spearhead-1-lancet-2024.json